Source: Pharmacy Times articles
The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial.
Read More
by MM360 Staff | Jun 3, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial.
Read More